Liz Ann Sonders warns that while the AI boom is stronger than the dot-com bubble, high expectations could lead to market shocks if companies fail to deliver growth. With Nvidia's $5 trillion valuation, the stakes are high.
In a recent podcast, OpenAI's Sam Altman defended the company's ambitious $1.4 trillion financial commitments amid skepticism about their revenue growth. With major AI deals and high expectations, Altman is confident about future profits but acknowledges risks.
This October is shaping up to be the worst in 27 years, with the box office failing to meet expectations. Halloween weekend is set to disappoint as the final World Series game draws audiences away from theaters. Can the industry recover?
Stock futures climbed on Thursday night as investors reacted to strong earnings from Amazon and Apple. With Amazon's cloud revenue soaring and Apple's fiscal forecasts shining, optimism is high despite recent market fluctuations.
Brian Kelly's time as LSU's head coach has come to a surprising end following a dismal season and internal strife. As the Tigers look for a new direction, what does this mean for their future?
Apple's latest earnings call reveals mixed results as iPhone revenue missed estimates, but the company is ramping up AI investments and anticipates strong growth in the holiday quarter. Will this lead to a comeback?
Nvidia has made headlines by becoming the first company to surpass a $5 trillion market value amid a booming AI sector. CEO Jensen Huang discusses future revenue expectations, while notable figures like Cramer and Starbucks' CEO weigh in.
Amazon's stock skyrocketed over 10% after reporting impressive Q3 earnings, surpassing analyst expectations with a 33% increase in adjusted earnings per share and a 20% growth in AWS sales. CEO Andy Jassy highlights strong momentum driven by AI.
Eli Lilly's stock surged 3.9% after an outstanding Q3 earnings report, surpassing analysts' expectations with $7.02 per share and $17.6 billion in sales. The company raised its yearly guidance, signaling strong growth potential.
Eli Lilly's third-quarter results exceeded estimates, driven by strong demand for Zepbound and Mounjaro. The company raised its revenue forecast, fueling a 5% rise in shares. Discover how Eli Lilly is maintaining its lead in the competitive obesity drug market.
